Research
Hormonal
Adipose tissue inflammation, driven by immune cell infiltration (macrophages, T cells) and pro-inflammatory cytokines (TNFα, IL-6), is a causal factor for systemic insulin resistance in obesity.
Obesity is not just about storing energy; it triggers inflammation in fat tissue that blocks insulin action. Reducing this inflammation, potentially through weight loss or anti-inflammatory strategies, can improve insulin sensitivity.
StrongSupportsVERY_HIGH confidence
Chronic overnutrition triggers uncontrolled inflammatory responses, leading to systemic low-grade inflammation and metabolic disorders, such as insulin resistance.
Why this rating
Extensive evidence from multiple animal models and human studies cited.
Source
Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders
Sung Sik Choe et al. · Frontiers in Endocrinology · 2016
DOI 10.3389/fendo.2016.00030
narrative_reviewCited 1,201×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adipocyte hypertrophy (enlargement) in white adipose tissue drives insulin resistance and metabolic disorders through inflammation, hypoxia, and lipotoxicity, whereas hyperplasia (increased adipocyte number) is associated with improved insulin sensitivity and metabolic health.Good
- Cold exposure induces 'beiging' of subcutaneous white adipose tissue, converting it to a brown-like phenotype that increases energy expenditure and improves metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →